Image of CDC Logo Image containing title: Tuberculosis Information CD-ROM   Image of people
 
1
jump over main navigation bar to content area
Home
TB Guidelines
Surveillance Reports
Slide Sets
TB-Related MMWRs and Reports
Education/Training Materials
Newsletters
Ordering Information
Help

U.S. Department of Health and Human Services logo

Treatment of Tuberculosis (2003)

This slide set was developed as an accompaniment to Treatment of Tuberculosis, a joint statement by CDC, the American Thoracic Society, and the Infectious Diseases Society of America. The slide set provides an overview of the current recommendations for the treatment of tuberculosis.

Download complete set (65 slides) in PowerPoint format - (581 KB)

NOTE: To download images to your local drive, right click on the image with your mouse, and choose "Save picture as". In the pop up menu that follows, navigate to a location where you would like to place the file, and click "Save."  To enlarge an image, or to navigate the presentation on the web, click on any image.


Slide 1: Treatment of Tuberculosis. Click here for larger image
d
Slide 2: Why a New TB Treatment Statement? Click here for larger image
d
Slide #1
Slide #2
Slide 3: What's New? (1). Click here for larger image
d
Slide 4: What's New? (2). Click here for larger image
d
Slide #3
Slide #4
Slide 5: What's New? (3). Click here for larger image
d
Slide 6: What's New? (4). Click here for larger image
d
Slide #5
Slide #6
Slide 7: Fundamental Responsibility and Approach in TB Treatment. Click here for larger image
d
Slide 8: Antituberculosis Drugs. Click here for larger image
d
Slide #7
Slide #8
Slide 9: Drug Abbreviations. Click here for larger image
d
Slide 10: Role of New Drugs (1). Click here for larger image
d
Slide #9
Slide #10
Slide 11: Role of New Drugs (2). Click here for larger image
d
Slide 12: Factors Guiding Treatment Initiation. Click here for larger image
d
Slide #11
Slide #12
Slide 13: When to Consider Treatment Initiation. Click here for larger image
d
Slide 14: Baseline Diagnostic Examinations for TB. Click here for larger image
d
Slide #13
Slide #14
Slide 15: Other Examinations to Conduct When TB Treatment is Initiated (1). Click here for larger image
d
Slide 16: Other Examinations to Conduct When TB Treatment is Initiated (2). Click here for larger image
d
Slide #15
Slide #16
Slide 17: IDSA/USPHS* Rating System for Treatment Recommendations. Click here for larger image
d
Slide 18: Treatment Regimens. Click here for larger image
d
Slide #17
Slide #18
Slide 19: Why Extend Continuation-Phase Treatment for 3 Months? Click here for larger image
d
Slide 20: When to Extend Continuation-Phase Treatment for 3 Months? Click here for larger image
d
Slide #19
Slide #20
Slide 21: Algorithm to Guide Duration of Continuation-Phase Treatment for Culture-Positive TB Patients. Click here for larger image
d
Slide 22: Algorithm to Guide Duration of Continuation-Phase Treatment for Culture-Positive TB Patients (continued). Click here for larger image
d
Slide #21
Slide #22
Slide 23: Treatment of Culture-Positive TB (1). Click here for larger image
d
Slide 24: Treatment of Culture-Positive TB (2). Click here for larger image
d
Slide #23
Slide #24
Slide 25: Treatment of Culture-Positive TB (3). Click here for larger image
d
Slide 26: Treatment of Culture-Positive TB (4). Click here for larger image
d
Slide #25
Slide #26
Slide 27: Algorithm to Guide Rifapentine (RPT) Use in the Continuation Phase. Click here for larger image
d
Slide 28: Algorithm to Guide Rifapentine (RPT) Use in the Continuation Phase (continued). Click here for larger image
d
Slide #27
Slide #28
Slide 29: Treatment of Culture-Positive TB: Rifapentine in Continuation Phase. Click here for larger image
d
Slide 30: Algorithm to Guide Treatment of Culture-Negative TB. Click here for larger image
d
Slide #29
Slide #30
Slide 31: Algorithm to Guide the Treatment of Culture-Negative TB (continued). Click here for larger image
d
Slide 32: Treatment of Culture-Negative TB. Click here for larger image
d
Slide #31
Slide #32
Slide 33: Treatment Monitoring (1). Click here for larger image
d
Slide 34: Treatment Monitoring (2). Click here for larger image
d
Slide #33
Slide #34
Slide 35: Treatment Monitoring (3). Click here for larger image
d
Slide 36: Determining Drug Completion (1). Click here for larger image
d
Slide #35
Slide #36
Slide 37: Determining Drug Completion (2). Click here for larger image
d
Slide 38: Management of Initial Phase Treatment Interruptions. Click here for larger image
d
Slide #37
Slide #38
Slide 39: Algorithm for Management of Treatment Interruptions in the Initial Phase. Click here for larger image
d
Slide 40: Management of Continuation Phase Treatment Interruptions. Click here for larger image
d
Slide #39
Slide #40
Slide 41: Management of Continuation Phase Treatment Interruptions. Click here for larger image
d
Slide 42: Algorithm for Management of Continuation Phase Treatment Interruptions. Click here for larger image
d
Slide #41
Slide #42
Slide 43: Common Adverse Reactions to Drug Treatment (1). Click here for larger image
d
Slide 44: Common Adverse Reactions to Drug Treatment (2). Click here for larger image
d
Slide #43
Slide #44
Slide 45: Common Adverse Reactions to Drug Treatment (3). Click here for larger image
d
Slide 46: Drug Interactions. Click here for larger image
d
Slide #45
Slide #46
Slide 47: Relapse (1). Click here for larger image
d
Slide 48: Relapse (2). Click here for larger image
d
Slide #47
Slide #48
Slide 49: Treatment Failure. Click here for larger image
d
Slide 50: Drug Resistance (1). Click here for larger image
d
Slide #49 Slide #50
Slide 51: Drug Resistance (2). Click here for larger image
d
Slide 52: Special Treatment Situations - HIV/AIDS . Click here for larger image
d
Slide #51
Slide #52
Slide 53: Special Treatment Situations (Children and Adolescents)(1). Click here for larger image
d
Slide 54: Special Treatment Situations: Children and Adolescents(2). Click here for larger image
d
Slide #53
Slide #54
Slide 55: Special Treatment Situations: Extrapulmonary TB. Click here for larger image
d
Slide 56: Special Treatment Situations: Pregnancy and Breastfeeding(1). Click here for larger image
d
Slide #55
Slide #56
Slide 57: Special Treatment Situations: Pregnancy and Breastfeeding(2). Click here for larger image
d
Slide 58: Special Treatment Situations: Renal Insufficiency and End-Stage Renal Disease(1). Click here for larger image
d
Slide #57
Slide #58
Slide 59: Special Treatment Situations: Renal Insufficiency and End-Stage Renal Disease(2). Click here for larger image
d
Slide 60: Special Treatment Situations: Hepatic Disease(1). Click here for larger image
d
Slide #59
Slide #60
Slide 61: Special Treatment Situations: Hepatic Disease(2). Click here for larger imaged Slide 62: Continuing Education Credits(1). Click here for larger imaged
Slide #61
Slide #62
Slide 63: Continuing Education Credits(2). Click here for larger imaged Slide 64: Treatment Guidelines Online Availability. Click here for larger imaged
Slide #63
Slide #64
Slide 65: Additional TB Resources. Click here for larger imaged  
Slide #65
 

 

 


Released October 2008
Centers for Disease Control and Prevention
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
Division of Tuberculosis Elimination - http://www.cdc.gov/tb

Please send comments/suggestions/requests to: hsttbwebteam@cdc.gov, or to
CDC/Division of Tuberculosis Elimination
Communications, Education, and Behavioral Studies Branch
1600 Clifton Rd., NE - Mailstop E-10, Atlanta, GA 30333